Please login to the form below

Not currently logged in
Email:
Password:

Gilead to acquire Calistoga

Gilead Sciences has entered into an agreement to acquire the biotech company Calistoga Pharmaceuticals in a deal worth up to $600m

Gilead Sciences has entered into an agreement to acquire the privately held biotech company Calistoga Pharmaceuticals in a deal that could be worth up to $600m

The deal, which is expected to close during the second quarter, calls for Gilead to pay $375m in cash upfront, with the potential for Calistoga to earn another $225m if certain milestones are achieved.

Seattle, Washington-based Calistoga is focused on developing treatments for cancer and inflammatory diseases. The company's lead product is CAL-101, an inhibitor of phosphoinositide-3 kinase that is currently in phase II studies as a single agent in patients with refractory indolent non-Hodgkin's lymphoma and in combination with rituximab in treatment-naïve elderly patients with chronic lymphocytic leukaemia.

The phosphoinositide-3 kinase pathway has been shown to be a central signalling pathway for cellular proliferation, survival and trafficking, according the company, which also has a number of selective PI3K inhibitors in preclinical development for other indications in oncology and inflammatory diseases.

Gilead has a portfolio of 13 marketed products, mainly in the areas of HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions. The Calistoga acquisition comes on the heels of the company's acquisitions last year of two other small biotech companies, CGI Pharmaceuticals and Arresto Biosciences, both of which are also developing drugs in the areas of oncology and inflammation.

Gilead acquired Arresto for $225m plus potential future payments based on achievement of certain sales levels. The company's lead product is a humanised monoclonal antibody being tested in early clinical studies as a treatment for idiopathic pulmonary fibrosis and advanced solid tumours.

Gilead paid $120m plus potential milestones for CGI in a bid to broaden its expertise in kinase biology and chemistry. CGI has generated a library of proprietary small molecule kinase inhibitors, with a lead preclinical compound that the company hopes could be effective for treating inflammatory diseases such as rheumatoid arthritis.

22nd February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics